JPRN-UMIN000047001
Completed
未知
Objective response, disease control rate, and progression-free survival, as surrogates of overall survival in trials evaluating immune checkpoint inhibitor regimens for advanced non-small cell lung cancer: individual-patient-data and study-level analyses - Objective response, disease control rate, and progression-free survival, as surrogates of overall survival in trials evaluating immune checkpoint inhibitor regimens for advanced non-small cell lung cancer: individual-patient-data and study-level analyses
Conditionsnon-small cell lung cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Yokohama City University Hospital
- Enrollment
- 3312
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
See below: N Horita. Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. Cancers (Basel). 2023 Jan; 15(1): 185.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •\[Independent\-patient\-level analysis part] Not defined. \[Study\-level analysis part] Non\-English article and conference abstract.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer PatientsCancerNCT05061342Fengming Kong5,000
Completed
Not Applicable
Correlation with overall survival of response rate (RR) and disease control rate (DCR) in phase II randomized controlled trials evaluating second- or later-line chemotherapy for advanced, locally advanced, and recurrent non-small cell lung cancer.SCLCJPRN-UMIN000040412Yokohama City University9,059
Completed
Phase 2
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)Renal Cell Carcinoma, MetastaticNCT02432846Mendus88
Unknown
Not Applicable
Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung CancerNon-small Cell Lung CancerNCT04945200Second Affiliated Hospital, School of Medicine, Zhejiang University50
Completed
Not Applicable
Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life DatabasesNCT03676257Institut Bergonié20,033